The 36-month beta value for TCRX is at 0.97. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 4 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TCRX is 43.83M, and currently, shorts hold a 5.25% of that float. The average trading volume for TCRX on June 04, 2025 was 569.41K shares.
TCRX) stock’s latest price update
The stock price of Tscan Therapeutics Inc (NASDAQ: TCRX) has jumped by 19.86 compared to previous close of 1.46. Despite this, the company has seen a gain of 22.38% in its stock price over the last five trading days. globenewswire.com reported 2025-05-28 that WALTHAM, Mass., May 28, 2025 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will present at the Jefferies Global Healthcare Conference being held at the Marriott Marquis in New York, NY on Wednesday, June 4, 2025 at 4:55 p.m. Eastern Time.
TCRX’s Market Performance
Tscan Therapeutics Inc (TCRX) has seen a 22.38% rise in stock performance for the week, with a 9.38% gain in the past month and a -13.37% plunge in the past quarter. The volatility ratio for the week is 9.20%, and the volatility levels for the past 30 days are at 6.50% for TCRX. The simple moving average for the past 20 days is 27.37% for TCRX’s stock, with a -46.89% simple moving average for the past 200 days.
Analysts’ Opinion of TCRX
Many brokerage firms have already submitted their reports for TCRX stocks, with BTIG Research repeating the rating for TCRX by listing it as a “Buy.” The predicted price for TCRX in the upcoming period, according to BTIG Research is $12 based on the research report published on May 16, 2024 of the previous year 2024.
Needham, on the other hand, stated in their research note that they expect to see TCRX reach a price target of $11. The rating they have provided for TCRX stocks is “Buy” according to the report published on May 13th, 2024.
Wedbush gave a rating of “Outperform” to TCRX, setting the target price at $8 in the report published on June 22nd of the previous year.
TCRX Trading at 25.38% from the 50-Day Moving Average
After a stumble in the market that brought TCRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -81.16% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TCRX starting from Lynx1 Capital Management LP, who purchase 1,388,794 shares at the price of $1.20 back on May 19 ’25. After this action, Lynx1 Capital Management LP now owns 6,746,141 shares of Tscan Therapeutics Inc, valued at $1,666,553 using the latest closing price.
Lynx1 Capital Management LP, the 10% Owner of Tscan Therapeutics Inc, purchase 1,200,000 shares at $1.20 during a trade that took place back on May 20 ’25, which means that Lynx1 Capital Management LP is holding 7,946,141 shares at $1,440,000 based on the most recent closing price.
Stock Fundamentals for TCRX
Current profitability levels for the company are sitting at:
- -31.6 for the present operating margin
- 0.59 for the gross margin
The net margin for Tscan Therapeutics Inc stands at -29.74. The total capital return value is set at -0.46. Equity return is now at value -78.93, with -45.85 for asset returns.
Based on Tscan Therapeutics Inc (TCRX), the company’s capital structure generated 0.32 points at debt to capital in total, while cash flow to debt ratio is standing at -1.23. The debt to equity ratio resting at 0.46. The interest coverage ratio of the stock is -41.42.
Currently, EBITDA for the company is -119.74 million with net debt to EBITDA at 0.45. When we switch over and look at the enterprise to sales, we see a ratio of 9.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.55.
Conclusion
In conclusion, Tscan Therapeutics Inc (TCRX) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
